Please provide your email address to receive an email when new articles are posted on . TAVR was superior to clinical surveillance in patients with asymptomatic severe aortic stenosis. Almost all ...

Please provide your email address to receive an email when new articles are posted on . Transcatheter aortic valve replacement for younger adults with severe aortic stenosis rose nearly ninefold from ...

The companies agreed to enhance access to technology from DASI, a leader in AI-driven predictive modeling and digital twin ...

Edwards Lifesciences has claimed a groundbreaking approval from the FDA that opens up its minimally invasive heart valve implants to patients before they begin to show cardiac symptoms. The company ...

Medtronic (NYSE: MDT) today announced the launch of its Stedi extra support guidewire for use with its Evolut TAVR platform.

The US Food and Drug Administration (FDA) has approved Edwards Lifesciences' SAPIEN 3 transcatheter aortic valve replacement (TAVR) platform for the treatment of patients with asymptomatic severe ...

The research team followed these patients for a median time of 2.4 years after TAVR and 4.9 years after SAVR to assess their outcomes. The primary focus was on 5-year survival rates. Secondary ...

WASHINGTON--(BUSINESS WIRE)--Edwards Lifesciences (NYSE: EW) today announced results from the EARLY TAVR Trial, the first randomized, controlled trial designed to study the best strategy for treating ...

New analysis from the EARLY TAVR trial showed patients between the age of 65 and 70 years old derived the most benefits of a strategy of early intervention with transcatheter aortic valve replacement ...

Pulmonary hypertension patients who undergo transcatheter aortic valve replacement are at a higher risk for mortality than those without pulmonary hypertension, according to a recent study.